Chemocentryx, Inc.

Edward J Sullivan

Andrew M K Pennell

Penglie Zhang

William L Thomas

Sreenivas Punna

Solomon Ungashe

Trevor T Charvat

Cheng Hu

Aaron Robert Novack

Anita Melikian

Jay Patrick Powers

Lianfa Li

Wei Yu Chen

Yibin Zeng

Kevin Lloyd Greenman

Xuefei Tan

Valeri Martichonok

John J Kim Wright

Andrew Mk Pennell

William D Thomas

Aaron Novack

Andrew MK Pennell

Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.

N-(2-(hetaryl)aryl)arylsulfonamides and N-(2-(hetaryl)hetaryl)arylsulfonamides

N-(2-(hetaryl)aryl)arylsulfonamides and n-(2-(hetaryl)hetaryl) arylsulfonamides

Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.

Triazolyl phenyl benzenesulfonamides

N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl)hetaryl arylsulfonamides

Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

Monocyclic and bicyclic compounds and methods of use

The present invention provides compounds having formula (I): 

OXO-imidazolidines as modulators of chemokine receptors

N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides

4-phenylpiperdine-pyrazole CCR1 antagonists

Piperidine derivatives and methods of use

Growing community of inventors

San Jose, CA, United States of America

Edward J Sullivan